Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunoprecise Antibodies Ltd (NQ: IPA ) 0.8500 +0.0200 (+2.41%) Streaming Delayed Price Updated: 3:54 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immunoprecise Antibodies Ltd < Previous 1 2 3 4 Next > ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures July 16, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 July 15, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer June 27, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ June 25, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology June 12, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery June 10, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) June 04, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results April 22, 2024 Via ACCESSWIRE ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments April 12, 2024 Via ACCESSWIRE InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications March 28, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments March 20, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* March 14, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology March 08, 2024 Via ACCESSWIRE IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology March 07, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 March 04, 2024 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery February 13, 2024 Via ACCESSWIRE ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms January 10, 2024 Via ACCESSWIRE IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* December 14, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Announces Closing of $1.265 Million Public Offering of Common Shares December 08, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14 December 07, 2023 Via ACCESSWIRE IPA Announces Pricing of $1.1 Million Public Offering of Common Shares December 06, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Announces Proposed Public Offering of Common Shares December 05, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call November 27, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery November 22, 2023 Via ACCESSWIRE BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research November 13, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™ October 25, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire IPA Provides Update on Growth Strategy and Recent Share Price Movement October 23, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data October 20, 2023 Via ACCESSWIRE How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research October 13, 2023 Via ACCESSWIRE ImmunoPrecise Antibodies Announces CFO Transition September 19, 2023 From ImmunoPrecise Antibodies Ltd. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.